How the FDA should protect its integrity from politics

Joshua Sharfstein ()

Nature, 2020, vol. 585, issue 7824, 161-161

Abstract: The US drug regulator is accused of misrepresenting data on COVID-19 therapies. A decade ago, it set criteria to ensure its decisions are driven by science.

Keywords: SARS-CoV-2; Medical research; Policy; Politics (search for similar items in EconPapers)
Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-020-02542-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:585:y:2020:i:7824:d:10.1038_d41586-020-02542-8

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-020-02542-8

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().